Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Hiroki Oyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3591-821X; OpenAlex author ID A5022400158. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 5 papers · 2026: 1 paper

Papers 9

  1. Intraductal Papillary Mucinous Neoplasm and Pancreatic Cancer: Opportunity Knocks Twice. First author DOI 10.14309/ajg.0000000000003677↗
  2. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  3. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  4. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Co-author DOI 10.1053/j.gastro.2025.04.032↗
  5. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  6. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… First author DOI 10.1136/gutjnl-2024-333259↗
  7. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  8. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106021↗
  9. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 9 shared papers, 2020–2026 · strength 1.80
  2. Tsuyoshi Hamada · 7 shared papers, 2020–2026 · strength 1.46
  3. Kazunaga Ishigaki · 7 shared papers, 2020–2025 · strength 1.17
  4. Mitsuhiro Fujishiro · 6 shared papers, 2023–2025 · strength 1.14
  5. Naminatsu Takahara · 6 shared papers, 2020–2025 · strength 1.03
  6. Tatsunori Suzuki · 5 shared papers, 2023–2025 · strength 0.88
  7. Maxim S. Petrov · 3 shared papers, 2025–2026 · strength 0.83
  8. Kei Saito · 3 shared papers, 2020–2025 · strength 0.45
  9. Yurie Tokito · 2 shared papers, 2025 · strength 0.38
  10. Koji Miyabayashi · 2 shared papers, 2025 · strength 0.38
  11. Go Endo · 2 shared papers, 2025 · strength 0.38
  12. Hidenori Kage · 2 shared papers, 2025 · strength 0.38
  13. Hiroyuki Isayama · 2 shared papers, 2020–2025 · strength 0.29
  14. Tomotaka Saito · 2 shared papers, 2020–2023 · strength 0.25
  15. Yukari Suzuki · 2 shared papers, 2020–2023 · strength 0.25
  16. Kazuhiko Koike · 2 shared papers, 2020–2023 · strength 0.23
  17. Dai Mohri · 1 shared paper, 2025 · strength 0.20
  18. Takashi Sasaki · 1 shared paper, 2025 · strength 0.20
  19. Saburo Matsubara · 1 shared paper, 2025 · strength 0.20
  20. Kiyoshi Hasegawa · 1 shared paper, 2025 · strength 0.20
  21. Tsuyoshi Takeda · 1 shared paper, 2025 · strength 0.20
  22. Yohei Masugi · 1 shared paper, 2025 · strength 0.20
  23. Ko Tomishima · 1 shared paper, 2025 · strength 0.20
  24. Makoto Ueno · 1 shared paper, 2025 · strength 0.20
  25. Takuma Iwata · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.